Treating patients with warfarin has always been a problem.  Even frequent regular INR testing fails to result in the majority of patients having clotting times within the recommended limits all the time. Now, all that could become a thing of … Continue reading

This was the title of a one day conference held to publicise the new anti-diabetic drug, dapagliflozin.  Quite a good title really seeing the novel approach of the drug to inhibit the reabsorption of glucose in the kidney leading to … Continue reading

The long term management of COPD has been affected by the latest “me-too” drug to be announced.  Until now the only long-acting anti-muscarinic drug available was tioptropium. Until now, Boehringer-Ingelheim have had this important field to themselves.  But now, Almirall … Continue reading

People interested in diabetes are always talking about eyes, feet or kidneys. At the present time, the interest is in kidneys. That’s not to say that eyes and feet have taken a back seat. It’s just that a new treatment … Continue reading

Linda Goldie, one of our Clinical Directors, is in Helsinki at the moment. Here’s what she’s up to: “I am here representing the general practice in which I work as a Diabetes Specialist Practice Nurse. This is  an EU research … Continue reading